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ABSTRACT Erythropoietin (EPO) is a therapeutic protein that is widely used to increase red blood cell production in chronic
kidney failure. EPO protein can be produced quickly with a transient gene expression system (TGE). However, the titer
produced using TGE is usually lower than the stable gene expression system (SGE). It has been known that TGE can be
improved by histone deacetylase inhibitors (iHDACs) such as valproic acid (VPA). This study was conducted to examine the
VPA effect on EPO protein expression in CHO KI suspension adapted cells and to find the optimum concentration of VPA
on transient EPO protein production. EPO proteins was quantified using the enzyme‐linked immunosorbent assay (ELISA)
method. The optimization of VPA concentrations showed that VPA increased the EPO protein yield by up to 2‐fold in
transient EPO production, and the optimum concentration of VPA was 4 mM. VPA optimization was very helpful to obtain
the maximum increase in the transiently expressed protein. Furthermore, this study can be used as a model to produce EPO
proteins or other recombinant proteins rapidly with TGE of CHO‐K1 suspension adapted cells..
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1 1. Introduction2
EPO is a glycoprotein that has hormone characteristic3
with 30,400 Dalton molecular weight (Yin and Blanchard4
2000). This protein is pivotal for stimulating the produc­5
tion of erythroid cells (Fried 2009). Many patients with6
kidney failure received this protein to increase red blood7
cell during hemodialysis. EPO treatment is also useful for8
patients with chemotherapy to reduce occurrence of ane­9
mia (Ashley et al. 2002; Stein 2003; Casadevall et al. 2004;10
Fried 2009).11
One of the main problems with cell line development12
for protein production using SGE system is that it is very13
laborious (Pham et al. 2006; Backliwal et al. 2008). On the14
other hand, TGE can be used as an alternative to produce15
protein in a more effective and convenient way. Particu­16
larly, its production time which is relatively fast, only re­17
quired about one to three weeks (Pham et al. 2006; Baldi18
et al. 2007; Carpentier et al. 2007; Geisse 2009). While19
the SGE technique can take up to several months.20
Previous studies have reported that TGE production21
can be improved by HDACs inhibitor, such as sodium bu­22
tyrate and VPA. Those compounds were known as booster23
agents in TGE to produce recombinant antibody in HEK24
293 and CHO DG44 mammalian cells (Allen et al. 2008; 25
Backliwal et al. 2008; Wulhfard et al. 2008). Since The 26
Food and Drug Administration (FDA) has approved the 27
use of VPA in human (Backliwal et al. 2008), hence the 28
use VPA in protein production as an alternative approach 29
can be considered, especially in TGE system. However, 30
the magnitude of the response of VPA may be diverse in 31
different cells. VPA increased transient anti­human RhD 32
antibody yield about 4­fold approximately in HEK293E 33
and 1.5­fold in CHO­DG44 (Backliwal et al. 2008). In re­ 34
lation to the ability of VPA to increase protein expression, 35
in this current study we attempted to increase the expres­ 36
sion of EPO by using VPA and optimize its concentration 37
in TGE system in CHO­K1 suspension adapted cells. 38
2. Materials and Methods 39
2.1. Cell culture 40
The CHO­K1 cells were used as the mammalian host ob­ 41
tained from Prof. Masashi Kawaichi, NAIST, Japan. The 42
cells were adapted into a suspension culture by cultur­ 43
ing the cells in the CHO­S­SFMII (Invitrogen, CA, USA), 44
serum­free medium (Wisnuwardhani et al. 2017). CHO­ 45
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K1 suspension cells were routinely cultured in 125­mL at46
37°C and 5% CO2.47
2.2. Transient transfection in CHO‐K1 suspension cells48
CHO­K1 suspension cells were transfected with pJ603­49
EPO plasmid containing 2 additional N links (Santoso50
et al. 2014). The cells were transfected using lipofectamin51
2000 according to themanufacturer’s protocol (Invitrogen,52
CA, USA). One day before transfection CHO­K1 suspen­53
sion cell was passaged in 20 mL CHO­S­SFMII serum­54
free medium with final density of 1x106 cells/ml in an55
125 mL Erlenmeyer flask. DNA­lipid solution with ra­56
tio 1:3 (2.5 μg DNA: 7.5 μl lipofectamin) was prepared in57
1 mL Opti­MEM medium. The DNA­lipid mixture was58
vortexed, incubated at room temperature for 20 min and59
added to the cells in a dropwise manner. Following incu­60
bation at 37°C for 6 hours, the cell was harvested at 300061
rpm for 5 min, resuspended in a sterile Erlenmeyer flask.62
The cell was then incubated on an orbital shaker at 37°C63
and 5% CO2 for overnight. EPO protein was analyzed by64
western blotting method.65
2.3. Protein characterization of EPO by N‐66
GlycosidaseF67
The presence of 5 N­links in EPO glycoprotein was char­68
acterized using N­glycosidaseF (Roche Mannheim, Ger­69
many) digestion. The EPO protein was digested using N­70
glycosidaseF according to themanufacturer’s protocol. As71
much as 20 µl (5 μg) of EPO protein was digested with 272
units of N­glycosidaseF in 50 µL total volume in sodium73
phosphate buffer with 20 mM final concentration, pH 7.2.74
Following incubation at 37°C for 120 min, using EPO pri­75
mary antibody, the mixture was analyzed using Western76
blot analysis.77
2.4. Optimation study of valproic acid (VPA) treatment78
Optimization of VPA concentrations followed the method79
of Wulhfard2010, with modifications in VPA concentra­80
tions. VPA salt (1M) (Sigma–Aldrich GbmH, Switzer­81
land) was prepared in water and filter sterilized using a82
0.22 μm filter (Millipore, Switzerland). VPA was added83
to the transfected cells at several concentrations (0 mM,84
1.25 mM, 2.5 mM, 3 mM, 3.75 mM, 4 mM, 5 mM or 1085
mM). The cells were incubated over night at 37°C and 5%86
CO2 and medium samples were collected for quantifica­87
tion. EPO protein was analyzed by slot blotting method88
and total protein was quantified by Coomassie (Bradford)89
Protein Assay method (Thermo Scientific, USA).90
2.5. VPA treatment in transiently transfected CHO‐K191
suspension cells92
VPA treatment in transiently transfected cells followed93
the method of Sinhadri2009, with modifications in mam­94
malian cell type, length of incubation time, and VPA con­95
centration. VPA was added to the transfected cells at 496
mM VPA concentrations. The cell was then incubated on97
an orbital shaker at 37°C and 5% CO2 for 12 days and su­98
pernatant was collected. The produced EPO protein was99
determined by EPO ELISA kit (Roche Mannheim, Ger­ 100
many). The control cell was untreated with VPA. Cell 101
number and viability were determined with the Trypan 102
Blue (Gibco, USA) exclusion method. 103
2.6. Slot blotting 104
The protein was blotted to nitrocellulose membranes 105
(GE Healthcare, USA) by slot blot apparatus. EPO 106
protein was detected using anti­hEPO antibody (Sigma, 107
St. Louis, USA), then was conjugated with the anti­ 108
rabbit IgG (whole molecule)­alkaline phosphatase anti­ 109
body (Promega, Madison, WI, USA). The bands will 110
be appeared by BCIP/NBT (5­bromo­4­chloro­3­indolyl­ 111
phosphate/nitro blue tetrazolium) (Promega, Madison, 112
USA) as coloring substrate 113
2.7. Quantification of EPO protein by ELISA 114
EPO proteins was quantified using the EPO ELISA kit 115
(Roche Mannheim, Germany). Culture supernatant was 116
added into the 96 wells plate that had been coated with 117
anti­EPO. Immunoreagent solution was added into all 118
wells and incubated at room temperature for 3 hours. 119
Plates were washed three times with washing solution. 120
EPO standard (Calbiochem, USA) was used to generate 121
a standard curve on each plate. TMB was used to deter­ 122
mine protein levels and plates were read on Multiskan Mi­ 123
croplate Reader (Thermo Scientific, USA) 124
3. Results and Discussion 125
3.1. Results 126
3.1.1 Protein characterization of EPO by N­ 127
GlycosidaseF 128
To prove that EPO protein has been obtained, the ex­ 129
pressed EPO protein was treated with N­GlycosidaseF to 130
release the N­linked carbohydrates. Data showed (Figure 131
1) that the rhEPO protein bands was ranged around 37­45 132
kDa which corresponds to the theoretical molecular mass 133
for the EPO that the exact molecular weight highly de­ 134
pends on the degree of glycosylation. Lane 2 it was rhEPO 135
without any treatments has ±37 kDa molecular weight, 136
while on lane 3 which was rhEPO with N­glycosidaseF 137
enzyme treatment has ±22 kDa molecular weight. 138
3.1.2 Optimization of VPA concentrations 139
To find the best concentration of VPA, in this study, sev­ 140
eral VPA concentrations were performed for optimization. 141
Culture supernatant was analyzed and the total protein was 142
measured using Bradford method. The result showed that 143
4 mM of VPA gave the highest hEPO expression (Fig­ 144
ure 2a). Accordingly, the total protein concentration also 145
showed the highest expression at 4 mM of VPA (Figure 146
2b). 147
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FIGURE1Western blot analysis of CHO‐K1 cells expressing rhEPO
protein, lane 1: Protein weight marker, lane 2: Digested rhEPO
protein by N‐glycosidaseF, lane 3: Undigested rhEPO protein by
N‐glycosidaseF.
(a)
(b)
FIGURE 2 Optimization VPA concentration on pJ603‐EPO tran‐
sient transfection. a. Supernatant culture was analyzed using in
slot blotting. b. Total protein chart was measured using Bradford
method.
3.1.3 The effect of VPA to yield, cell density, viability148
cell CHO­K1149
Simultaneously, after six hours of transfection with pJ603­150
EPO plasmid, VPA was added to the cell culture with the151
final concentration of 4 mM. Samples were collected for152
every 3 days for 12 days period. Figure 3 showed that153
the result of VPA affected the protein yield, cell density154
and viability. The highest yield of EPO was obtained at 155
day 12 which was about 15 mg/L. Meanwhile, the yield 156
without VPA, at day 12, reached only 7,5 mg/L (Figure 157
3a). This data suggested that VPA can raise of EPO pro­ 158
tein yield up to two­fold compared to control. While VPA 159
had positive effects on the yield, the addition of VPA to 160
the cell culture decreased cell density and viability (Fig­ 161
ure 3b and 3c). Cell growth of untreated cell increased 162
strongly and reached maximum at day four. This increase 163
was then followed by continual decrease until day 12. Pro­ 164
file of cell growth of VPA treated cell was almost similar 165
to the untreated one except that the peak at day four was 166
much lower (Figure 3b). Inversely proportional to the cell 167
density profile, cell viability of treated and untreated ones, 168
continuously decreases until it reaches its lowest point on 169
day 12 which was about 20 percent. 170
3.1.4 Discussion 171
EPO protein that extracellularly expressed in CHO­SFM 172
media was successfully detected by anti­EPO at a size 173
of about 37 kDa. Furthermore, in order to find out that 174
the EPO protein produced in CHO K1 cells is the protein 175
of our interest, characterization was carried out using N­ 176
glycosidase. EPO protein digestion with N­glycosidase F 177
will remove most of the carbohydrates from the protein 178
(Egrie and Browne 2001) and reduce molecular weight by 179
around 15 kDa. The results seen in the Figure 1 showed a 180
decrease of EPO molecular weight when treated with gly­ 181
cosidase enzymes. Decreasing molecular weight of the 182
protein to approximately 22 kDa indicates the existence 183
of asparagine linked glycan chains. Thus, it is proven that 184
this protein is an EPO protein that contains glycan chains. 185
Technological approach of transient gene expression be­ 186
comes more interesting to produce protein recombinant 187
rapidly inmammalian cells, especially CHO andHEK­293 188
cells (Pham et al. 2006; Baldi et al. 2007). 189
Previous studies had reported that transiently trans­ 190
fected CHO cell treated with VPA can enhance recom­ 191
binant protein yield. However, the growth of CHO cell 192
has also been reported to be inhibited by VPA addition 193
(Backliwal et al. 2008; Wulhfard et al. 2010). Based on 194
that background, the application of VPA on transient ex­ 195
pression for enhancement of protein expression has to be 196
carefully optimized. In this current optimization study, it 197
was found that 4 mM of VPA concentration gave the high­ 198
est yield of EPO (Figure 2a). This result corresponds to 199
the profile of total protein concentration where the high­ 200
est yield was also found to be at 4 mM of VPA (Figure 201
2b). After reaching the optimum concentration (4 mM of 202
VPA), the yield decreased which, in this case, presumably 203
caused by the blocking of cell growth by VPA. Working 204
on HEK 293 cell expressing TNFR:Fc fusion protein, Sin­ 205
hadri (2009) reported that the 3.75 mM VPA exhibited the 206
highest amount of IgG.Meanwhile, Backliwal et al. (2008) 207
have found that the best concentration of VPA to produce 208
anti­RhD antibody was 4 mM in HEK 293 cell and 500 209
μM in CHO DG44 cell. 210
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(a)
(b)
(c)
FIGURE3The effect of VPAon protein yield, cell density and viabil‐
ity. a. EPO protein yield was measured using ELISA. b. Cell density
was revealed between VPA and non‐VPA treatment on CHO‐K1
suspension cell. c. Cell viability was showed between VPA and
non‐VPA treatment on CHO‐K1 suspension cell.
Overall, the data gained in this study exhibited that211
VPA has an influence on TGE where the EPO protein pro­212
duction was increased up to two­fold after adding 4 mM213
of VPA (Figure 3a). Previous study confirms that VPA214
enhanced monoclonal antibody recombinant yield about 4215
fold on HEK293 cell and 1.5 fold on CHO DG44 (Back­216
liwal et al. 2008). Fan et al. (2005) stated that the im­217
provement of this yield may have to do with the ability of218
VPA to block class I and II histone deasetylases (HDACs),219
and induce histone acetylation both in vitro and in vivo220
(Michaelis et al. 2004; Marchion et al. 2005).221
(Watson et al. 2014) reported that the removal of pos­222
itive charge of histones by acetylation lowers the inter­ 223
action of the N termini of histones with the negatively 224
charged phosphate groups of DNA. As a result, the struc­ 225
ture of chromatin becomes more relaxed and promotes 226
greater levels of gene transcription. This relaxation sub­ 227
sequently will make it easier for transcription site to be at­ 228
tached by transcription initiation factors and subsequently 229
the gene of our interest can be highly expressed to be trans­ 230
lated into protein (Haberland et al. 2009). 231
In line with previous studies, our data shown that VPA 232
has a strong influence of TGE, in this case, the transient 233
expression of EPO in CHO­K1 suspension adapted cells 234
increase by up to 2 folds. This study also demonstrated that 235
the optimization of VPA concentration was very helpful 236
to obtain the maximum increase in the expression of our 237
protein of interest. 238
Based on the research conducted by Sami et al. (2008), 239
VPA can inhibit the cell cycle in the G1/G0 phase on HeLa 240
cells. Inhibition of the cell cycle can affect the stability of 241
transient genes in cells. Instability of gene on cells cause 242
the lost of gene. According to a review by Lecharduer and 243
Lechardeur and Lukacs (2006), the plasmid DNAwill lost 244
during the subsequent cell divisions in transient transfec­ 245
tion processes. The loss of plasmid DNA in cells makes 246
the target protein unable to be expressed. Therefore, the 247
low expression of the EPO protein in CHO­K1 cells with­ 248
out VPA may be due to cell division causing the loss of 249
EPO gene, but this still needs further study. While the 250
CHO­K1 cells were treated with VPA addition exhibited 251
high protein expression although low viability and den­ 252
sity of cells. This is probably due to the presence of VPA 253
that can make the cell remains in the G1/G0 phase for a 254
while. In this phase, cells do not carry out cell division 255
processes but remain actively expressing proteins until cell 256
death (apoptosis) occurs. 257
4. Conclusions 258
Valproic acid increases EPO protein titer produced tran­ 259
siently in CHO­K1 suspension adapted cells by up to two­ 260
fold compared to the one without the addition of VPA; 261
and 4 mM of VPA was found to be the optimum con­ 262
centration. VPA addition on transient recombinant pro­ 263
tein expression is highly efficient for obtaining high pro­ 264
tein yield. Therefore, this study is important as a model to 265
produce EPO protein or another recombinant protein pro­ 266
duced transiently in CHO­K1 suspension adapted cells. 267
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